Autopsy report · NCT01015456
The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
Cause of deathSafety
“Data Safety Monitoring Board concerning of the participants' safety”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years before it stopped.
- 59 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Conditions
- Lupus Nephritis
- Interventions
- mycophenolate sodium; cyclophosphamide
- Participants
- 59
- Sites
- 3
- Countries
- Thailand
Trials that died the same way
- High Resolution Imaging of Cerebral Vasculature by Functional Micro-Doppler Sonography During Brain Surgery
“recommandation of the Data Safety monitoring Board” - Lithium in Multiple System Atrophy
“Data Monitoring Committee decision on 22nd August 2011 for safety issues” - Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
“following a recommendation from the data safety and monitoring board due to safety concerns and a tendency towards futility.” - Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
“New Safety Information” - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
“Following a recommendation from the Data Safety Monitoring Board (DSMB).”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.